Page 6 - Eric Althoff News Today

ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis. 1 Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting ...

Novartis International AG: Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene Novartis secures development and commercialization rights in North America, Europe, and Japan Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations Tislelizumab already approved for patients with classical Hodgkins lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials und...

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth Novartis secures development and commercialization rights in North America, Europe, and Japan Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations Tislelizumab already approve...

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.

HCO News By Eric Althoff CHARLESTON, S.C.—A new 625,000-square-foot women’s and children’s care facility is officially open at the Medical University of South Carolina (MUSC) in Charleston. The Shawn Jenkins Children’s Hospital & Pearl Tourville Women’s Pavilion encompasses 10 stories and has a patient capacity of 250 persons. The tower stands adjacent to an existing four-story medical podium. The MUSC campus specializes in solutions for rare healthcare issues that can be especially s...

HCO News MURFREESBORO, Tenn. —Nashville-based healthcare real estate development firm Oman-Gibson Associates (OGA) has broken ground on a new ambulatory surgery center (ASC) and medical office building (MOB) in the city of Murfreesboro, located 30 miles southeast of Tennessee’s capital city. OGA is developing the ASC in concert with United Surgical Partners International (USPI), whose home offices are in Dallas. The healthcare construction project, which will be sited adjacent to the existi...

Novartis International AG: Novartis receives complete response letter from U.S. FDA for inclisiran The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related conditions No onsite inspection was conducted of the single third-party facility in question. If a facility inspection is needed, FDA will define an approach once safe travel may resume based on public...

NOVARTIS AG CHF0.50(REGD) Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval could make Entresto the first therapy indi...

(2) The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval could make Entresto the first therapy indicated for use in treatment of patients with both major types of chronic heart failure: HFpEF and HFrEF; and the only chronic heart failure treatment studied in both conditions against active comparators 1,2 HFpEF patients currently have no approved treatme...

Search jobs 16-Dec-2020 Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF EAST HANOVER, December 15, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto ® (sacubitril/valsartan) in treatment of patients with heart failur...